Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer.

Simona Nanni, Alfredo Pontecorvi, Carmen Priolo, Antonella Farsetti, 33183, DI MEDICINA E CHIRURGIA "A.GEMELLI" FACOLTA', ROMA - Dipartimento di Medicina e chirurgia traslazionale, V Benvenuti, DI MEDICINA E CHIRURGIA "A.GEMELLI" FACOLTA', A Grasselli, A Aiello, S Mattiussi, C Colussi, V Lirangi, B Illi, M D'Eletto, Am Cianciulli, M Gallucci, P De Carli, S SentinelliM Mottolese, P Carlini, L Stringari, S Finn, E Mueller, G Arcangeli, C Gaetano, Mc Capogrossi, Rp Donnorso, S Bacchetti, A Sacchi, M Loda

Risultato della ricerca: Contributo in rivistaArticolo in rivista


The identification of biomarkers that distinguish between aggressive and indolent forms of prostate cancer (PCa) is crucial for diagnosis and treatment. In this study, we used cultured cells derived from prostate tissue from patients with PCa to define a molecular mechanism underlying the most aggressive form of PCa that involves the functional activation of eNOS and HIFs in association with estrogen receptor beta (ERbeta). Cells from patients with poor prognosis exhibited a constitutively hypoxic phenotype and increased NO production. Upon estrogen treatment, formation of ERbeta/eNOS, ERbeta/HIF-1alpha, or ERbeta/HIF-2alpha combinatorial complexes led to chromatin remodeling and transcriptional induction of prognostic genes. Tissue microarray analysis, using an independent cohort of patients, established a hierarchical predictive power for these proteins, with expression of eNOS plus ERbeta and nuclear eNOS plus HIF-2alpha being the most relevant indicators of adverse clinical outcome. Genetic or pharmacologic modulation of eNOS expression and activity resulted in reciprocal conversion of the transcriptional signature in cells from patients with bad or good outcome, respectively, highlighting the relevance of eNOS in PCa progression. Our work has considerable clinical relevance, since it may enable the earlier diagnosis of aggressive PCa through routine biopsy assessment of eNOS, ERbeta, and HIF-2alpha expression. Furthermore, proposing eNOS as a therapeutic target fosters innovative therapies for PCa with NO inhibitors, which are employed in preclinical trials in non-oncological diseases.
Lingua originaleEnglish
pagine (da-a)1093-1108
Numero di pagine16
Stato di pubblicazionePubblicato - 2009


  • prostater cancer


Entra nei temi di ricerca di 'Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer.'. Insieme formano una fingerprint unica.

Cita questo